Epigral Ltd

Meeting Details

• Date: Wednesday, 14 October 2026
• Mode: Video Conferencing
• Type: One-on-One meeting
• Organizer: Elara Securities(India)Pvt Ltd
• Place: N.A.
• Purpose: Intimation of One-on-One meeting with Investor/Analyst

Epigral Limited: Trading Window closes from 1 October 2026 until expiry of 48 hours after the declaration of the Un-Audited Financial Results for the Second Quarter and Half Year ended 30 September 2026

Meeting Details

• Date: Monday, 21 September 2026
• Type/Mode: Group conference, in-person (physical) in Mumbai
• Event/organiser: Anand Rathi Annual Flagship Conference: G-200 Summit 2026
• Company participants: Chairman and Managing Director (Epigral Ltd)
• Purpose: Participation in conference for investor interaction

Meeting Details

• Date: 3 September 2026; Time: not specified.
• Mode: on-site investor/analyst plant visit.
• Location: Dahej, Gujarat.
• Organizer: Bellwether Capital.

Purpose

• Purpose: Investor/Analyst plant visit to Epigral.

Participants

• Key company participants: Company Secretary and Compliance Officer.

Notes

• Schedule is subject to change.
• No unpublished price sensitive information will be discussed.

Meeting Details

• Date: Thu, 20 Aug 2026.
• Time: Not disclosed.
• Mode: One-on-One.
• Location: Ahmedabad.
• Organizer: Incred Research Services Pvt. Ltd.

Participants

• Key company participants: Company Secretary and Compliance Officer.

Purpose

• Purpose: One-on-one investor/analyst meeting to discuss earnings and corporate presentations.

Additional Notes

• Earnings and Corporate Presentations are available on the company website.

Meeting Details

• Date: Wednesday, 12 August 2026; Time not specified.
• Type/Mode: Group conference; in-person in Mumbai.
• Event: EMKAY Confluence 2026.
• Key participants: Company Secretary & Compliance Officer.
• Purpose: Participation in investor conference.

Meeting Details

• Date: Monday, 3 August 2026
• Time: Not disclosed
• Type/Mode: One-on-One meeting; physical (Ahmedabad)
• Organizer: VVD Asset Managers; event: Investor/Analyst meeting

Participants

• Company participants: not specified in filing

Purpose

• Purpose: One-on-One investor/analyst meeting

Additional Notes

• Presentations: Latest Earnings and Corporate Presentations on epigral.com
• No unpublished price sensitive information will be shared or discussed

Financial Performance

• Revenue rose 15% YoY to INR709 crores in Q1 FY27.
• EBITDA rose 10% to INR179 crores; margin 25% vs 27% in Q1 FY26.
• PAT grew 25% to INR99 crores; adjusted Q1 FY26 PAT was INR79 crores.
• ROCE stood at 16% as on 30 June; excluding capex, ROCE is 18%.
• Net debt to EBITDA 0.8x as on 30 June; 0.6x as on 30 June FY25.
• Net debt at INR474 crores vs INR439 crores on 30 June FY25.
• Capex spent in Q1 FY27 was INR62 crores.

Capex and Projects

• Board approved two new capex projects: Epoxy Resin & Formulations capacity 125,000 tpa.
• Multipurpose plant to manufacture downstream products of epichlorohydrin and chlorotoluene value chain.
• Pilot facility for epoxy resin and MPP to be commissioned by September 2026.
• 50% of epichlorohydrin to be consumed in-house; 50% to be sold.
• Total post-expansion capacity expected around 1 lakh tonnes (net KTA).
• Demand for epoxy and CPVC products projected to maintain double-digit CAGR.
• Epoxy market size estimated at 2.5–3 lakh tonnes; Europe post-FTA potential.
• Pilot facility for epoxy resin and MPP to enable customer trials ahead of scale-up.

Outlook and Guidance

• Epoxy and CPVC markets to grow; ROCE target around 20%.
• Peak revenue for both projects projected INR1,000–1,500 crores.
• FY27 and FY28 capex guidance around INR400 crores each.
• Tax rate expected around 25%.
• Power strategy: no new captive plant; sourcing from solar and wind hybrids.

Q&A Highlights

• Epoxy capacity expansion includes LER and value-added products; total post-expansion around 1 lakh tonnes.
• Capex breakup for INR600 crores not disclosed; combined capex guidance provided.
• 50% epichlorohydrin consumed in-house; 50% sold in market.
• Pilot plant to enable trials; commissioning by September FY27.
• Epoxy margins expected to be lower; ROCE target around 20%.
• Capex funding: 60% internal, 40% debt.
• ECH realization currently around INR180–185; Q1 ECU realization around INR35,000; Q4 FY26 ECU around INR30,000.
• Power: not investing in captive power; 20 MW solar and wind hybrid agreements.
• CPVC margins affected by PVC MIP; pass-through to customers gradual.
• Chlorotoluenes: base products sold; derivatives under MPP ramp to 500 crores revenue.
• Estimated total top-line from chlorotoluenes and MPP project INR700–800 crores.

Meeting Details

• Date and time: conference call on 27 July 2026 at 5:00 p.m.
• Type and mode: group conference call; audio recording available.
• Event: Q1 FY27 Results Conference Call.
• Key participants: Company Secretary & Compliance Officer.
• Purpose: discuss Q1 FY27 results with investors.
• Availability: audio recording on Epigral's results page.